Skip to content

Application of PIVKA-II in the diagnosis of recurrent liver cancer

Application of PIVKA-II in the diagnosis of recurrent liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070874
Enrollment
Unknown
Registered
2023-04-25
Start date
2023-04-25
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Sponsors

The Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Patients diagnosed as hepatocellular carcinoma by pathological diagnosis after radical surgery; 2. PIVKA-II and AFP tests were performed before radical surgery and during outpatient visit, and the data of other laboratory tests were complete. 3. Age and gender were not limited;

Exclusion criteria

Exclusion criteria: Exclusion criteria : 1. patients with positive pathological margins; 2. Patients with primary tumors of other organs; 3.Patients took warfarin or vitamin K1; 4. Patients with acute hepatitis, gonadoembryoma or other diseases that can cause elevated alpha-fetoprotein

Design outcomes

Primary

MeasureTime frame
PIVKA-II;AFP;

Secondary

MeasureTime frame
MVI;Degree of differentiation;GGT;ALP;ALB;PT;AST;ALT;WBC;RBC;PLT;

Countries

China

Contacts

Public ContactShuguang Zhu

The Third Affiliated Hospital of Sun Yat-sen University

za200909@163.com+86 13929528606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026